STOCK TITAN
  1. Home
  2. News
  3. MEIP

MEI Pharma, Inc. - MEIP STOCK NEWS

Welcome to our dedicated page for MEI Pharma news (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on MEI Pharma stock.

MEI Pharma, Inc. (NASDAQ: MEIP), based in San Diego, is an oncology-focused biotechnology company dedicated to the clinical development of innovative cancer therapies. The company's mission is to improve the quality of life and outcomes for cancer patients through the development of novel treatments.

Core Business and Drug Candidates:

  • Pracinostat: MEI Pharma's lead drug candidate, Pracinostat, is an oral histone deacetylase (HDAC) inhibitor. It has received breakthrough therapy designation from the FDA when used in combination with azacitidine for treating patients with newly diagnosed acute myeloid leukemia (AML) who are aged 75 or above, or those unfit for intensive chemotherapy.
  • ME-401 (formerly PWT143): A next-generation oral phosphatidylinositide 3-kinase delta (PI3K delta) inhibitor being developed for patients with recurrent chronic lymphocytic leukemia (CLL) or follicular non-Hodgkin's lymphoma (NHL).
  • ME-344: This isoflavone-based mitochondrial inhibitor is being explored for the treatment of HER2-negative breast cancer, demonstrating MEI Pharma's commitment to addressing unmet needs in oncology.

Recent Achievements and Partnerships: MEI Pharma has made significant strides in its clinical programs. The breakthrough therapy designation for Pracinostat underscores its potential impact in the treatment landscape of AML. In addition, strategic collaborations with leading research institutions and oncology experts bolster the company's development capabilities and market positioning.

Financial Condition: MEI Pharma continues to focus on advancing its clinical pipeline while maintaining a prudent financial strategy. The company’s investment in cutting-edge research and clinical trials is supported by strategic funding initiatives, ensuring sustained progress in its mission to combat cancer.

Current Projects: The clinical development of Pracinostat, ME-401, and ME-344 remains at the forefront of MEI Pharma’s efforts. Ongoing clinical trials and research are expected to provide valuable data, guiding future regulatory submissions and potential market approvals.

With a robust pipeline and a clear focus on innovative cancer therapies, MEI Pharma, Inc. stands as a significant player in the oncology sector. For more information, please visit www.meipharma.com.

News

MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

Rhea-AI Summary
MEI Pharma, Inc. (Nasdaq: MEIP) has announced the design of the ongoing Phase 1b study of ME-344, a mitochondrial oxidative phosphorylation (OXPHOS) inhibitor, in combination with bevacizumab (Avastin®) in refractory metastatic colorectal cancer patients. The study will be presented at the 2024 ASCO Gastrointestinal Cancers Symposium. The combination is intended to create metabolic synthetic lethality to address known resistance mechanisms to standard-of-care cancer therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
conferences clinical trial
-
News

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023

Rhea-AI Summary
MEI Pharma, Inc. (Nasdaq: MEIP) announced clinical data from the monotherapy dose escalation stage of the ongoing Phase 1 study evaluating voruciclib, a selective oral cyclin-dependent kinase 9 (“CDK9”) inhibitor, alone and in combination with venetoclax in patients with acute myeloid leukemia or B-cell malignancies. Safety profile observed suggests no overlapping toxicity. Initial results from correlative studies demonstrate on-target reductions in Mcl-1 and RNA Pol II p-S2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
clinical trial
-
News

MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights

Rhea-AI Summary
MEI Pharma (MEIP) reports strong clinical study support for drug candidates voruciclib and ME-344, with data from Phase 1 trials expected in 2024. Recent highlights include dosing of the first patient in a Phase 1b study for ME-344, and an abstract presentation at the ASH Annual Meeting. Financially, the company recognized revenue of $65.3 million for the quarter ended September 30, 2023, and reported net income of $56.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
earnings
News

MEI Pharma to Present at the Stifel 2023 Healthcare Conference

Rhea-AI Summary
MEI Pharma, Inc. (MEIP) to present at Stifel 2023 Healthcare Conference, offering business update. Investors invited to live webcast on November 15 at 8:35 AM Eastern Time. Replay available on www.meipharma.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.22%
Tags
conferences
-
News

MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock

Rhea-AI Summary
MEI Pharma, Inc. (Nasdaq: MEIP) has announced a special cash dividend of $1.75 per share of common stock, payable on December 6, 2023. The dividend will be characterized for tax purposes as a return of capital to shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.57%
Tags
dividends
-
News

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

Rhea-AI Summary
MEI Pharma announced that clinical data from the Phase 1 study of voruciclib will be presented at the ASH Annual Meeting. The study evaluates the CDK9 inhibitor alone and in combination with venetoclax in patients with AML or B-cell malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
none
News

MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital

Rhea-AI Summary
MEI Pharma and Anson Funds and Cable Car Capital have entered into a cooperation agreement. MEI Pharma plans to pay a dividend of $1.75 per share to stockholders and authorize a second return of capital of approximately $9.33 million. The company has appointed two directors designated by Anson and Cable Car and formed a Capital Allocation Committee. Anson and Cable Car have agreed to withdraw their consent solicitation and vote for the company's director nominees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
none
-
News

MEI Pharma Recommends Stockholders Not to Consent

Rhea-AI Summary
MEI Pharma files definitive consent revocation statement and urges stockholders to disregard Anson Advisors and Cable Car Capital's consent solicitation materials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
-
News

MEI Pharma Adopts Limited-Duration Stockholder Rights Plan

Rhea-AI Summary
MEI Pharma adopts a limited-duration stockholder rights plan in response to Anson Advisors and Cable Car Capital accumulating approximately 19.9% of outstanding shares. The plan aims to protect stockholders' long-term value and prevent a self-interested group from taking control. The plan becomes exercisable if any person acquires 20% or more of the company's outstanding common stock. The Rights Plan is effective immediately and will expire on September 30, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
News

MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions

Rhea-AI Summary
MEI Pharma, Inc. responds to consent solicitation by Anson Advisors Inc. and Cable Car Capital LLC. Board focused on advancing voruciclib and ME-344 programs with potential to improve cancer outcomes. Anson and Cable Car's agenda to strip cash and lack of understanding of MEI's business raises concerns. MEI Board evaluates request for new record date and finds no basis. MEI to provide formal recommendation on consent solicitation and election of directors in upcoming SEC filings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
none

FAQ

What is the current stock price of MEI Pharma (MEIP)?

The current stock price of MEI Pharma (MEIP) is $2.5 as of December 20, 2024.

What is the market cap of MEI Pharma (MEIP)?

The market cap of MEI Pharma (MEIP) is approximately 16.3M.

What is MEI Pharma, Inc.?

MEI Pharma is a San Diego-based biotechnology company focused on developing innovative cancer therapies.

What is Pracinostat?

Pracinostat is MEI Pharma's lead drug candidate, an oral HDAC inhibitor for treating acute myeloid leukemia (AML) in certain patients.

What other drug candidates does MEI Pharma have?

MEI Pharma's pipeline includes ME-401, a PI3K delta inhibitor, and ME-344, a mitochondrial inhibitor.

What recent achievements has MEI Pharma made?

Pracinostat received breakthrough therapy designation from the FDA for certain AML patients.

What partnerships does MEI Pharma have?

MEI Pharma collaborates with leading research institutions and oncology experts to advance its clinical programs.

How is MEI Pharma financially supported?

MEI Pharma maintains a prudent financial strategy, supported by strategic funding initiatives for its research and clinical trials.

Where can I find more information about MEI Pharma?

More information can be found on their official website: www.meipharma.com.

What are the main focuses of MEI Pharma's current projects?

MEI Pharma is focused on the clinical development of Pracinostat, ME-401, and ME-344 through ongoing trials and research.

Where is MEI Pharma located?

MEI Pharma is headquartered in San Diego, California.

What is ME-401 used for?

ME-401 is an oral inhibitor being developed for recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma.

Stock MEIP logo
MEI Pharma, Inc.

Nasdaq:MEIP

MEIP Rankings

#5391 Ranked by Market Cap
N/A Ranked by Dividends

MEIP Stock Data

16.33M
6.58M
1.31%
41.04%
1.22%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO